Legend Biotech (NASDAQ:LEGN) Stock

Legend Biotech

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech Corporation - American Depositary Shares

Legend Biotech Corp

Macro strategist Raoul Pal has shared his outlook for crypto investors amid recent market volatility, emphasizing that patience and proper risk management are essential for <a href="https://www.benzinga.com/money/bitcoin-price-prediction">surviving this correction</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=W7ZL-nFoynw">podcast</a> on March 1, Pal described the downturn as part of a normal bull market correction, driven by tightening global financial conditions. He explained that &#8220;Financial conditions tightened last year due to the dollar rallying in anticipation of Trump and rising rates ahead of potential tariffs.&#8221;
His core advice centers on risk management: &#8220;If you&#8217;re using leverage, you are going to get blown out and you&#8217;re going to lose control of your tokens.&#8221;
Pal referenced his M2 money supply model, developed with analyst Julian Batella, which has accurately predicted Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) price movements with a 10-week lag. 
Addressing Solana's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) 53% decline, Pal dismissed concerns that the asset is failing. He called claims that Solana is a &#8220;scam coin&#8221; or &#8220;dead coin&#8221; nonsense, arguing that SOL remains a deep and robust protocol.
 He also pointed out that its price looks undervalued relative to global M2 trends.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/03/44143660/howard-lutnick-says-president-definitely-thinks-theres-a-bitcoin-strategic-reserve">Howard Lutnick Says &#8216;President Definitely Thinks There&#8217;s A Bitcoin Strategic Reserve&#8217;</a>
What's Next: Despite short-term turbulence, Pal remains optimistic about the bigger picture.
He expects the market to recover by mid-March, calling the current phase the &#8220;healing stage&#8221; and predicts that April, May, and June will mark the second phase of the Banana Zone, ushering in significant bullish price action across the crypto space. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/25/03/44174606/jpmorgan-questions-viability-of-us-crypto-reserve-cites-issues-with-smaller-tokens">JPMorgan Questions Viability of US Crypto Reserve, Cites Issues With Smaller Tokens</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$SOL

Raoul Pal Sees Bitcoin, Solana In 'Healing Stage', Predicts Market Recovery In Q2

Outlook
•First Quarter Guidance: Forecasts 7% to 15% sequential revenue growth, revenues of $28.2 million - $30.2 million, Adjusted EBITDA2 loss of $1.8 million to $0.8 million and positive cash flow
•Full Year: Forecasts significant improvements in revenue, adjusted EBITDA, and cash flow

Guidance

Telos Expects Q1 Revenue Of $28.2 M-$30.2M Vs $32.46M Est

Dividends

Safe And Green Development Declares Stock Dividend

Barclays analyst Matt Miksic maintains Baxter Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) with a Overweight and raises the price target from $39 to $41.

Price Target

Analyst Ratings

Barclays Maintains Overweight on Baxter Intl, Raises Price Target to $41

Arthur J. Gallagher & Co Acquires The Remaining Shares Of Philippines-Based Philpacific Insurance Brokers & Manager; Terms Not Disclosed

Keybanc analyst Jason Celino upgrades Paycom Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>) from Sector Weight to Overweight and announces $245 price target.

Upgrades

PAYC

Keybanc Upgrades Paycom Software to Overweight, Announces $245 Price Target

CLSK

Reported March 7, 2025: CleanSpark Will Join S&P SmallCap 600, Effective Prior To The Open Of Trading On Monday, March 24, 2025

Smoker Friendly Adds Both VLN and Smoker Friendly Branded VLN Reduced Nicotine Content Products to its Store Lineup
MOCKSVILLE, N.C., March 10, 2025 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), a tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced that it has signed an agreement with Smoker Friendly, one of its largest customers, to launch Smoker Friendly VLN branded reduced nicotine content cigarette products that will become the first VLN partner brand.
The introduction of Smoker Friendly VLN and 22nd Century VLN in Smoker Friendly outlets will be one of the first presentations of gold and menthol SKU's that introduce the new VLN branding.

XXII

22nd Century Signs An Agreement With Smoker Friendly To Launch Smoker Friendly VLN Branded Reduced Nicotine Content Cigarette Products That Will Become The First VLN Partner Brand

Earnings

Earnings Beats

Telos Q4 2024 Adj. EPS $(0.04) Beats $(0.09) Estimate, Sales $26.372M Beat $25.623M Estimate

Barclays analyst Brandt Montour maintains Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) with a Equal-Weight and lowers the price target from $18 to $14.

BALY

Barclays Maintains Equal-Weight on Ballys, Lowers Price Target to $14

Eligible shoppers can now pay over time for coveted sneakers, apparel, accessories and more with Affirm's customized biweekly and monthly payment plans
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fstockx.com%2F&amp;esheet=54221089&amp;newsitemid=20250310115375&amp;lan=en-US&amp;anchor=StockX&amp;index=1&amp;md5=afc7619100411b206c93b9c6e02f9861">StockX</a>, a global resale marketplace for current culture products, today announced that it has partnered with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affirm.com%2F&amp;esheet=54221089&amp;newsitemid=20250310115375&amp;lan=en-US&amp;anchor=Affirm&amp;index=2&amp;md5=fdcce344d968844000767a95850628c4">Affirm</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>), the payment network that empowers consumers and helps merchants drive growth. Eligible StockX shoppers in the U.S. can now access Affirm's flexible payment plans when purchasing coveted items from top brands like adidas, Supreme, Gucci, and more.

AFRM

Affirm And StockX Partner To Offer New, Transparent Payment Offering

Buybacks

ELMD

Electromed Announces Its Board of Directors Authorizes The Repurchase Of Up To $5M Of Electromed Common Stock.

Oppenheimer analyst Scott Schneeberger maintains WillScot Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WSC#NASDAQ">WSC</a>) with a Outperform and lowers the price target from $41 to $38.

Oppenheimer Maintains Outperform on WillScot Holdings, Lowers Price Target to $38

Analysts' ratings for SLM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLM#NASDAQ">SLM</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $33.11, a high estimate of $38.00, and a low estimate of $29.00. Marking an increase of 9.96%, the current average surpasses the previous average price target of $30.11. 
<img src="https://www.benzinga.com/files/images/story/2025/1741611638_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of SLM among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffery Harte</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jon Afstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Michael Kaye</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Giuliano Bologna</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Sanjay Sakhrani</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jeffery Harte</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$32.00</td>
<td>$26.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SLM. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of SLM compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of SLM's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of SLM's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on SLM analyst ratings.</a>
<h2>Unveiling the Story Behind SLM</h2>
SLM Corp is an education solutions company. It business is to originate and service loans to students and their families to finance the cost of their education. The provide Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
<h3>SLM's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: SLM's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -11.97%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: SLM's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 27.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): SLM's ROE stands out, surpassing industry averages. With an impressive ROE of 5.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): SLM's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.36%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: SLM's debt-to-equity ratio surpasses industry norms, standing at 3.37. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down SLM: 9 Analysts Share Their Views

14 analysts have shared their evaluations of Progressive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Progressive and provided 12-month price targets. The average target is $294.93, accompanied by a high estimate of $318.00 and a low estimate of $256.00. Witnessing a positive shift, the current average has risen by 0.53% from the previous average price target of $293.38.
<img src="https://www.benzinga.com/files/images/story/2025/1741611628_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A clear picture of Progressive's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$318.00</td>
<td>$333.00</td>
</tr>
<tr>
<td>Harry Fong</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$315.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$264.00</td>
<td>$261.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$307.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$313.00</td>
<td>$302.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$294.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$261.00</td>
<td>$277.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$256.00</td>
<td>$251.00</td>
</tr>
<tr>
<td>C. Gregory Peters</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$267.00</td>
<td>$273.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$302.00</td>
<td>$299.00</td>
</tr>
<tr>
<td>Bob Huang</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Progressive. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Progressive compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Progressive's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PGR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Progressive analyst ratings.</a>
<h2>Delving into Progressive's Background</h2>
Progressive underwrites private and commercial auto insurance and specialty lines; it has almost 20 million personal auto policies in force and is one of the largest auto insurers in the United States. Progressive markets its policies through independent insurance agencies in the US and Canada and directly via the internet and telephone. Its premiums are split roughly equally between the agent and the direct channel. The company also offers commercial auto policies and entered homeowners insurance through an acquisition in 2015.
<h3>Breaking Down Progressive's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Progressive's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 20.04%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Progressive's net margin excels beyond industry benchmarks, reaching 11.63%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Progressive's ROE stands out, surpassing industry averages. With an impressive ROE of 8.93%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Progressive's ROA stands out, surpassing industry averages. With an impressive ROA of 2.23%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Progressive's debt-to-equity ratio is below the industry average at 0.27, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 14 Analyst Projections For Progressive

Barclays analyst Saket Kalia initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Overweight rating and announces Price Target of $27.

Initiation

SAIL

Barclays Initiates Coverage On SailPoint with Overweight Rating, Announces Price Target of $27

Mizuho analyst Gregg Moskowitz initiates coverage on SailPoint (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Neutral rating and announces Price Target of $25.

Mizuho Initiates Coverage On SailPoint with Neutral Rating, Announces Price Target of $25

PPBT

Purple Biotech Q4 EPADS $(0.26)

Mizuho analyst Vijay Rakesh initiates coverage on SanDisk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) with a Outperform rating and announces Price Target of $60.

SNDK

Mizuho Initiates Coverage On SanDisk with Outperform Rating, Announces Price Target of $60

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Linda Tsai initiated coverage on SailPoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with a Buy rating and announced a price target of $26. SailPoint shares closed at $22.05 on Friday. <a href="https://www.benzinga.com/quote/SAIL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Jason Gursky initiated coverage on Karman Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRMN#NYSE">KRMN</a>) with a Buy rating and announced a price target of $42. Karman shares closed at $28.78 on Friday. <a href="https://www.benzinga.com/quote/KRMN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on Pulmonx Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNG#NASDAQ">LUNG</a>) with a Buy rating and announced a price target of $17. Pulmonx shares closed at $7.48 on Friday. <a href="https://www.benzinga.com/quote/LUNG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Tim Anderson initiated coverage on Aardvark Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AARD#NASDAQ">AARD</a>) with a Buy rating and announced a price target of $22. Aardvark Therapeutics shares closed at $10.13 on Friday. <a href="https://www.benzinga.com/quote/AARD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Morgan Stanley analyst Keith Weiss initiated coverage on SailPoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NASDAQ">SAIL</a>) with an Equal-Weight rating and announced a price target of $26. SailPoint shares closed at $22.05 on Friday. <a href="https://www.benzinga.com/quote/SAIL/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying LUNG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-1024x562.png" alt="" class="wp-image-816610" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/10085530/image-50.png 1148w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44187903/top-2-consumer-stocks-that-could-blast-off-this-quarter">Top 2 Consumer Stocks That Could Blast Off This Quarter</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

AARD

KRMN

LUNG

This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Health Care

Press Releases

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

General

Legend Biotech to Establish New, State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

Legend Biotech to Host Investor Conference Call on Third Quarter 2024 Results

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

Comments

Legend Biotech

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL